Version 1
: Received: 20 December 2023 / Approved: 21 December 2023 / Online: 21 December 2023 (12:13:14 CET)
How to cite:
Contreras-Zentella, M.L.; Butanda-Ochoa, A.; Sánchez-Sevilla, L.; Díaz-Paredes, R.; Hernández-Muñoz, R. Involvement of Liver Redox State in the Zi-Dovudine-Induced Hepatic Steatosis and Its Partial Prevention by Adenosine. Preprints2023, 2023121657. https://doi.org/10.20944/preprints202312.1657.v1
Contreras-Zentella, M.L.; Butanda-Ochoa, A.; Sánchez-Sevilla, L.; Díaz-Paredes, R.; Hernández-Muñoz, R. Involvement of Liver Redox State in the Zi-Dovudine-Induced Hepatic Steatosis and Its Partial Prevention by Adenosine. Preprints 2023, 2023121657. https://doi.org/10.20944/preprints202312.1657.v1
Contreras-Zentella, M.L.; Butanda-Ochoa, A.; Sánchez-Sevilla, L.; Díaz-Paredes, R.; Hernández-Muñoz, R. Involvement of Liver Redox State in the Zi-Dovudine-Induced Hepatic Steatosis and Its Partial Prevention by Adenosine. Preprints2023, 2023121657. https://doi.org/10.20944/preprints202312.1657.v1
APA Style
Contreras-Zentella, M.L., Butanda-Ochoa, A., Sánchez-Sevilla, L., Díaz-Paredes, R., & Hernández-Muñoz, R. (2023). Involvement of Liver Redox State in the Zi-Dovudine-Induced Hepatic Steatosis and Its Partial Prevention by Adenosine. Preprints. https://doi.org/10.20944/preprints202312.1657.v1
Chicago/Turabian Style
Contreras-Zentella, M.L., Rodolfo Díaz-Paredes and Rolando Hernández-Muñoz. 2023 "Involvement of Liver Redox State in the Zi-Dovudine-Induced Hepatic Steatosis and Its Partial Prevention by Adenosine" Preprints. https://doi.org/10.20944/preprints202312.1657.v1
Abstract
Zidovudine (AZT) has significantly reduced the mortality and morbidity rates among AIDS patients, but it has been associated with hepatotoxicity. AZT treatment has been linked to disrupted lipid and glucose metabolism, and the enhancement of pro-inflammatory chemokines and other mediators, which can lead to liver steatosis. In contrast, the administration of adenosine (ADO) has proven to be an effective hepatoprotector against both acute and chronic liver damage. Therefore, present study was aimed to investigate the harmful effects of chronic AZT administration and the beneficial effects of the co-administered ADO. Chronic oral AZT administration did not induce hyperglycemia or dyslipidemia, but serum liver marker enzyme activities were increased, as well as evidence of liver steatosis and inflammation. These findings were associated with low insulin and glucagon levels, elevated serum levels of pro-inflammatory cytokines and disruptions in cell redox states in these animals. ADO co-administration attenuated the deleterious effects induced by AZT: blocking the production of inflammatory molecules, increasing serum insulin and glucagon levels, and restoring liver cellular redox state. Then, blood insulin levels seemed to be greatly influenced by the cellular redox state, which was altered by AZT administration. This alteration is likely to be connected to mitochondrial integrity and metabolism.
Medicine and Pharmacology, Gastroenterology and Hepatology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
